Project documents | Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18] | Guidance | NICE

Documents

A list of downloadable documents created during development.

Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): update to stakeholders

Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): update to stakeholders ^{PDF 35 KB} 18 February 2009

Rheumatoid arthritis - adalimumab, etanercept and infliximab: letter to consultees and commentators regarding the appeal panel's decision

Rheumatoid arthritis - adalimumab, etanercept and infliximab: letter to consultees and commentators regarding the appeal panel's decision ^{PDF 38 KB} 24 November 2008

Rheumatoid arthritis - adalimumab, etanercept and infliximab: appeal panel's decision

Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): appeal announcement

Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): appeal announcement
Abbot Laboratories Ltd
Appeals received ^{PDF 44 KB} 29 September 2008
Initial scrutiny letter ^{PDF 83 KB} 29 September 2008
Response to scrutiny letter ^{PDF 312 KB} 29 September 2008
Final scrutiny letter ^{PDF 35 KB} 29 September 2008
Arthritis and Musculoskeletal Alliance (ARMA)
Appeals received ^{PDF 123 KB} 29 September 2008
Initial scrutiny letter ^{PDF 79 KB} 29 September 2008
Response to scrutiny letter ^{PDF 123 KB} 29 September 2008
Final scrutiny letter ^{PDF 97 KB} 29 September 2008
National Rheumatoid Arthritis Society (NRAS)
Appeals received ^{PDF 372 KB} 29 September 2008
Initial scrutiny letter ^{PDF 116 KB} 29 September 2008
Response to scrutiny letter ^{PDF 153 KB} 29 September 2008
Final scrutiny letter ^{PDF 96 KB} 29 September 2008
Royal College of Nursing (RCN)
Appeals received ^{PDF 114 KB} 29 September 2008
Initial scrutiny letter ^{PDF 91 KB} 29 September 2008
Response to scrutiny letter ^{PDF 24 KB} 29 September 2008
Final scrutiny letter ^{PDF 66 KB} 29 September 2008
Schering- Plough Ltd
Appeals received ^{PDF 597 KB} 29 September 2008
Final scrutiny letter ^{PDF 59 KB} 29 September 2008
Wyeth Pharmaceuticals
Appeals received ^{PDF 705 KB} 29 September 2008
Initial scrutiny letter ^{PDF 240 KB} 29 September 2008
Response to scrutiny letter ^{PDF 677 KB} 29 September 2008
Final scrutiny letter ^{PDF 88 KB} 29 September 2008

Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): final appraisal determination

Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): final appraisal determination
Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): final appraisal determination information
Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): final appraisal determination ^{PDF 234 KB} 21 July 2008
Response to consultee, commentator and public comments on the ACD and comments from website consultation ^{PDF 317 KB} 21 July 2008
Consultee and commentator comments on the ACD
Abbott Laboratories ^{PDF 79 KB} 21 July 2008
Arthritis and Musculoskeletal Alliance (ARMA) - submission and letters supporting submission from Arthritis Care, BSR, NRAS and RCN ^{PDF 305 KB} 21 July 2008
Arthritis Care ^{PDF 55 KB} 21 July 2008
Department of Health ^{PDF 12 KB} 21 July 2008
National Rheumatoid Arthritis Society (including comments from members) ^{PDF 397 KB} 21 July 2008
NHS Quality Improvement Scotland ^{PDF 16 KB} 21 July 2008
Roche ^{PDF 44 KB} 21 July 2008
Royal College of Nursing ^{PDF 22 KB} 21 July 2008
Schering-Plough ^{PDF 177 KB} 21 July 2008
Somerset PCT ^{PDF 11 KB} 21 July 2008
Welsh Assembly Government ^{PDF 12 KB} 21 July 2008
Wyeth Pharmaceuticals ^{PDF 222 KB} 21 July 2008
NICE Guideline Development Group ^{PDF 51 KB} 21 July 2008

Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): appraisal consultation

Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): evaluation report
Overview
Summary of the documents presented to the Committee ^{PDF 106 KB} 29 April 2008
Overview information
Overview ^{PDF 321 KB} 29 April 2008
Decision Support Unit reports
Modelling the Cost Effectiveness of Sequential Use of the TNF Inhibitors in the Management of Rheumatoid Arthritis: An Update ^{PDF 264 KB} 29 April 2008
The Sequential use of TNF-alpha inhibitors, prepared by Dr Allan Wailoo (School of Health and Related Research, University of Sheffield) for the NICE Decision Support Unit ^{PDF 395 KB} 29 April 2008
The Effectiveness of Non Biologic DMARDs After Anti TNF-alpha Inhibitor Failure information
The Effectiveness of Non Biologic DMARDs After Anti TNF-alpha Inhibitor Failure ^{PDF 205 KB} 29 April 2008
Further cost-effectiveness analysis of sequential TNF inhibitors for rheumatoid arthritis patients information
Further cost-effectiveness analysis of sequential TNF inhibitors for rheumatoid arthritis patients ^{PDF 486 KB} 29 April 2008
Sequential TNF-alpha Inhibitors and Non Biologic DMARDs - Analysis of the National Databank for Rheumatic Diseases information
Sequential TNF-alpha Inhibitors and Non Biologic DMARDs - Analysis of the National Databank for Rheumatic Diseases ^{PDF 171 KB} 29 April 2008
Consultee and Commentator comments information
Abbott Laboratories ^{PDF 306 KB} 29 April 2008
British National Formulary ^{PDF 17 KB} 29 April 2008
British Society for Rheumatology ^{PDF 198 KB} 29 April 2008
Department of Health ^{PDF 13 KB} 29 April 2008
National Rheumatoid Arthritis Society ^{PDF 26 KB} 29 April 2008
Royal College of Nursing ^{PDF 23 KB} 29 April 2008
Schering-Plough ^{PDF 144 KB} 29 April 2008
Wyeth Pharmaceuticals ^{PDF 119 KB} 29 April 2008
A clinical advisor to the Assessment Group ^{PDF 12 KB} 29 April 2008

Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): notification of decision to split the FAD

Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): notification of decision to split the FAD ^{PDF 18 KB} 02 January 2008

Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): appeal panel decision

Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): appeal panel decision ^{PDF 131 KB} 12 June 2007

Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): final scope

Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): final scope ^{PDF 112 KB} 26 November 2004